Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options

Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

O’Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T. H., Hochhaus, A., Hughes, T. P., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,550 · see citing works

Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

Druker, B. J., Guilhot, F., O’Brien, S. G., Gathmann, I., Kantarjian, H. M., Gattermann, N., Deininger, M. W., Silver, R. T., Goldman, J. M., Stone, R. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062867 · Cited by 3,473 · see citing works

Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification

Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · see citing works

Hematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia

Kantarjian, H., Sawyers, C. L., Hochhaus, A., Guilhot, F., Schiffer, C. A., Gambacorti-Passerini, C. B., Niederwieser, D. W., Resta, D. J., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,005 · see citing works

Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase

Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785 · see citing works

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760 · see citing works

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

Shah, N. P., Nicoll, J. M., Nagar, B., Gorre, M. E., PAQUETTE, R. L., Kuriyan, J., & Sawyers, C. L. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00096-x · Cited by 1,608 · see citing works

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl

Weisberg, E., Manley, P. W., Breitenstein, W., Brüggen, J., Cowan‐Jacob, S. W., Ray, A., Huntly, B. J. P., Fabbro, D., Fendrich, G., Hall–Meyers, E., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.007 · Cited by 1,494 · see citing works

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

Baccarani, M., Cortes, J. E., Pane, F., Niederwieser, D. W., Saglio, G. N., Apperley, J. F., Cervantes, F., Deininger, M. W., Gratwohl, A. A., Guilhot, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0779 · Cited by 1,276 · see citing works

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

O’Hare, T., Shakespeare, W. C., Zhu, X., Eide, C. A., Rivera, V. M., Wang, F., Adrian, L. T., Zhou, T., Huang, W.-S., Xu, Q., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.09.028 · Cited by 1,268 · see citing works

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

Baccarani, M. (2006) · Blood · doi:10.1182/blood-2006-02-005686 · Cited by 1,265 · see citing works

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,197 · see citing works

<i>In vitro</i> Activity of Bcr-Abl Inhibitors AMN107 and BMS-354825 against Clinically Relevant Imatinib-Resistant Abl Kinase Domain Mutants

O'Hare, T., Walters, D. K., Stoffregen, E. P., Jia, T., Manley, P. W., Mestan, J., Cowan-Jacob, S. W., Lee, F. Y., Heinrich, M. C., Deininger, M. W. N., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0259 · Cited by 1,036 · see citing works

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

Hochhaus, A., Kreil, S., Corbin, A. S., Rosée, P. G. L., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N. C. P., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 907 · see citing works

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

Mahon, F., Deininger, M. W., Schultheis, B. S., Chabrol, J., Reiffers, J. J., Goldman, J. M., & Melo, J. V. (2000) · Blood · doi:10.1182/blood.v96.3.1070 · Cited by 776 · see citing works

Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769 · see citing works

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765 · see citing works

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

Branford, S., Rudzki, Z., Walsh, S., Parkinson, I., Grigg, A., Szer, J., Taylor, K. M., Herrmann, R., Seymour, J. F., Arthur, C., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2896 · Cited by 763 · see citing works

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Kantarjian, H. M., Giles, F. J., Gattermann, N., Bhalla, K. N., Alimena, G., Palandri, F., Ossenkoppele, G. J., Nicolini, F. E., O’Brien, S. G., Litzow, M. R., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080689 · Cited by 740 · see citing works

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571

Donato, N. J., Wu, J. Y., Stapley, J., Gallick, G. E., Lin, H., Arlinghaus, R. B., & Talpaz, M. (2002) · Blood · doi:10.1182/blood.v101.2.690 · Cited by 663 · see citing works

Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study

Larson, R. A., Druker, B. J., Guilhot, F., O’Brien, S. G., Rivière, G., Krahnke, T., Gathmann, I., & Wang, Y. (2008) · Blood · doi:10.1182/blood-2007-10-116475 · Cited by 644 · see citing works

Active transport of imatinib into and out of cells: implications for drug resistance

Thomas, J., Wang, L., Clark, R. E., & Pirmohamed, M. (2004) · Blood · doi:10.1182/blood-2003-12-4276 · Cited by 642 · see citing works

Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia

Apperley, J. F. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70342-x · Cited by 641 · see citing works

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

Copland, M., Hamilton, A., Elrick, L. J., Baird, J. W., Allan, E. K., Jordanides, N., Barow, M., Mountford, J. C., & Holyoake, T. L. (2006) · Blood · doi:10.1182/blood-2005-07-2947 · Cited by 635 · see citing works

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

O’Hare, T., Eide, C. A., & Deininger, M. W. (2007) · Blood · doi:10.1182/blood-2007-03-066936 · Cited by 634 · see citing works

Mechanisms of Autoinhibition and STI-571/Imatinib Resistance Revealed by Mutagenesis of BCR-ABL

Azam, M., Latek, R. R., & Daley, G. Q. (2003) · Cell · doi:10.1016/s0092-8674(03)00190-9 · Cited by 617 · see citing works

Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia

Picard, S., Titier, K., Étienne, G., Teilhet, E., Ducint, D., Bernard, M., Lassalle, R., Marit, G., Reiffers, J. J., Bégaud, B., et al. (2006) · Blood · doi:10.1182/blood-2006-07-036012 · Cited by 610 · see citing works

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Hochhaus, A., Kantarjian, H. M., Baccarani, M., Lipton, J. H., Apperley, J. F., Druker, B. J., Facon, T. T. F., Goldberg, S. L., Cervantes, F., Niederwieser, D. W., et al. (2006) · Blood · doi:10.1182/blood-2006-09-047266 · Cited by 601 · see citing works

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet

Soverini, S., Hochhaus, A., Nicolini, F. E., Gruber, F., Lange, T., Saglio, G. N., Pane, F., Müller, M. C., Ernst, T., Rosti, G., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326405 · Cited by 593 · see citing works

Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years

Rousselot, P. H., Huguet, F., Réa, D., Legros, L., Cayuela, J., Maarek, O., Blanchet, O., Marit, G., Gluckman, É., Reiffers, J. J., et al. (2006) · Blood · doi:10.1182/blood-2006-03-011239 · Cited by 538 · see citing works

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Soverini, S., Colarossi, S., Gnani, A., Rosti, G., Castagnetti, F., Poerio, A., Iacobucci, I., Amabile, M., Abruzzese, E., Orlandi, E. M., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1516 · Cited by 507 · see citing works

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

Marín, D., Ibrahim, A. R., Lucas, C., Gerrard, G., Wang, L., Szydlo, R., Clark, R. E., Apperley, J. F., Milojković, D., Bua, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6565 · Cited by 489 · see citing works

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification

le Coutre, P., Tassi, E., Varella‐Garcia, M., Barni, R., Mologni, L., Cabrita, G. J. M., Marchesi, E., Supino, R., & Gambacorti-Passerini, C. B. (2000) · Blood · doi:10.1182/blood.v95.5.1758.005a41_1758_1766 · Cited by 484 · see citing works

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

Weisberg, E., Manley, P. W., Mestan, J., Cowan‐Jacob, S. W., Ray, A., & Griffin, J. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603170 · Cited by 484 · see citing works

Pharmacokinetics and Pharmacodynamics of Imatinib in a Phase I Trial With Chronic Myeloid Leukemia Patients

Peng, B., Hayes, M., Resta, D. J., Racine-Poon, A., Druker, B. J., Talpaz, M., Sawyers, C. L., Rosamilia, M., Ford, J., Lloyd, P. M., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.03.050 · Cited by 471 · see citing works

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

Cortes, J. E., Kantarjian, H. M., Brümmendorf, T. H., Kim, D., Turkina, A., Shen, Z.-X., Pasqüini, R., Khoury, H. J., Arkin, S., Volkert, A., et al. (2011) · Blood · doi:10.1182/blood-2011-05-355594 · Cited by 462 · see citing works

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

Hanfstein, B., Müller, M. C., Hehlmann, R., Erben, P., Lauseker, M., Fabarius, A. C., Schnittger, S., Haferlach, C., Göhring, G., Proetel, U., et al. (2012) · Leukemia · doi:10.1038/leu.2012.85 · Cited by 415 · see citing works

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

Shah, N. P., Skaggs, B. J., Branford, S., Hughes, T. P., Nicoll, J. M., PAQUETTE, R. L., & Sawyers, C. L. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30890 · Cited by 415 · see citing works

Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants

Redaelli, S., Piazza, R., Rostagno, R., Magistroni, V., Perini, P., Marega, M., Gambacorti-Passerini, C. B., & Boschelli, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8853 · Cited by 398 · see citing works

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

Bradeen, H. A., Eide, C. A., O'Hare, T., Johnson, K. J., Willis, S. G., Lee, F. Y., Druker, B. J., & Deininger, M. W. (2006) · Blood · doi:10.1182/blood-2006-02-004580 · Cited by 393 · see citing works

Imatinib plus Peginterferon Alfa-2a in Chronic Myeloid Leukemia

Preudhomme, C., Guilhot, J., Nicolini, F. E., Guerci‐Bresler, A., Huguet, F., Maloisel, F., Coiteux, V., Gardembas, M., Berthou, C., Vekhoff, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1004095 · Cited by 389 · see citing works

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Talpaz, M., Bekele, N. B., O'Brien, S. M., Zhou, X., Luthra, R., Garcia‐Manero, G., Giles, F. J., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404318 · Cited by 385 · see citing works

In vitro and In vivo Activity of SKI-606, a Novel Src-Abl Inhibitor, against Imatinib-Resistant Bcr-Abl+ Neoplastic Cells

Puttini, M., Coluccia, A. M. L., Boschelli, F., Cleris, L., Marchesi, E., Donella‐Deana, A., Ahmed, S., Redaelli, S., Piazza, R., Magistroni, V., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1199 · Cited by 376 · see citing works

ABL Mutations in Late Chronic Phase Chronic Myeloid Leukemia Patients With Up-Front Cytogenetic Resistance to Imatinib Are Associated With a Greater Likelihood of Progression to Blast Crisis and Shorter Survival: A Study by the GIMEMA Working Party on Chronic Myeloid Leukemia

Soverini, S., Martinelli, G., Rosti, G., Bassi, S., Amabile, M., Poerio, A., Giannini, B., Trabacchi, E., Castagnetti, F., Testoni, N., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.531 · Cited by 373 · see citing works

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

Guilhot, F., Apperley, J. F., Kim, D., Bullorsky, E. O., Baccarani, M., Roboz, G. J., Amadori, S., Souza, C. A. D., Lipton, J. H., Hochhaus, A., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046839 · Cited by 365 · see citing works

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Hochhaus, A., Baccarani, M., Deininger, M. W., Apperley, J. F., Lipton, J. H., Goldberg, S. L., Corm, S., Shah, N. P., Cervantes, F., Silver, R. T., et al. (2008) · Leukemia · doi:10.1038/leu.2008.84 · Cited by 350 · see citing works

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Khoury, H. J., Cortes, J. E., Kantarjian, H. M., Gambacorti-Passerini, C. B., Baccarani, M., Kim, D., Zaritskey, A. Y., Countouriotis, A., Besson, N., Leip, E. P., et al. (2012) · Blood · doi:10.1182/blood-2011-11-390120 · Cited by 322 · see citing works

Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib

Corbin, A. S., Rosée, P. G. L., Stoffregen, E. P., Druker, B. J., & Deininger, M. W. (2003) · Blood · doi:10.1182/blood-2002-12-3659 · Cited by 310 · see citing works

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Willis, S. G., Lange, T., Demehri, S., Otto, S., Crossman, L. C., Niederwieser, D. W., Stoffregen, E. P., McWeeney, S. K., Kovacs, I., Park, B. S., et al. (2005) · Blood · doi:10.1182/blood-2005-03-1036 · Cited by 298 · see citing works

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

le Coutre, P., Ottmann, O. G., Giles, F. J., Kim, D., Cortes, J. E., Gattermann, N., Apperley, J. F., Larson, R. A., Abruzzese, E., O’Brien, S. G., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083196 · Cited by 291 · see citing works

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

Cortes, J. E., Jabbour, E. J., Kantarjian, H. M., Yin, C. C., Shan, J., O'Brien, S. M., Garcia‐Manero, G., Giles, F. J., Breeden, M., Reeves, N., et al. (2007) · Blood · doi:10.1182/blood-2007-03-080838 · Cited by 291 · see citing works

Phase II Study of Low-Dose Decitabine in Patients With Chronic Myelogenous Leukemia Resistant to Imatinib Mesylate

Issa, J. J., Gharibyan, V., Cortes, J. E., Jelı́nek, J., Morris, G., Verstovšek, S., Talpaz, M., Garcia‐Manero, G., & Kantarjian, H. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.981 · Cited by 288 · see citing works

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Müller, M. C., Cortes, J. E., Kim, D., Druker, B. J., Erben, P., Pasqüini, R., Branford, S., Hughes, T. P., Radich, J. P., Ploughman, L., et al. (2009) · Blood · doi:10.1182/blood-2009-04-214221 · Cited by 287 · see citing works

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph + leukemia in mice

Hu, Y., Swerdlow, S., Duffy, T. M., Weinmann, R. S., Lee, F. Y., & Li, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606509103 · Cited by 272 · see citing works

Mechanisms of Resistance to Imatinib and Second-Generation Tyrosine Inhibitors in Chronic Myeloid Leukemia

Milojković, D., & Apperley, J. F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1068 · Cited by 265 · see citing works

Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia

Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer Control · doi:10.1177/107327480901600204 · Cited by 246 · see citing works

NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia

Kimura, S. H., Naito, H., Segawa, H., Kuroda, J., Yuasa, T., Sato, K., Yokota, A., Kamitsuji, Y., Kawata, E., Ashihara, E., et al. (2005) · Blood · doi:10.1182/blood-2005-06-2209 · Cited by 238 · see citing works

Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy

Cortes, J. E., Talpaz, M., Giles, F. J., O'Brien, S. M., Rios, M. B., Shan, J., Garcia‐Manero, G., Faderl, S. H., Thomas, D. A., Wierda, W., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2790 · Cited by 236 · see citing works

Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center

Lahaye, T., Riehm, B., Berger, U., Paschka, P., Müller, M. C., Kreil, S., Merx, K., Schwindel, U., Schoch, C., Hehlmann, R., et al. (2005) · Cancer · doi:10.1002/cncr.20922 · Cited by 231 · see citing works

Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients.

Gambacorti-Passerini, C. B., Zucchetti, M., Russo, D., Frapolli, R., Verga, M., Bungaro, S., Tornaghi, L., Rossi, F., Pioltelli, P. E., Pogliani, E., et al. (2003) · PubMed · Cited by 228 · see citing works

Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily

Kantarjian, H. M., Pasqüini, R., Lévy, V., Jootar, S., Hołowiecki, J., Hamerschlak, N., Hughes, T. P., Bleickardt, E. W., Dejardin, D., Cortes, J. E., et al. (2009) · Cancer · doi:10.1002/cncr.24504 · Cited by 216 · see citing works

Detection of BCR-ABL kinase mutations in CD34+ cells from chronic myelogenous leukemia patients in complete cytogenetic remission on imatinib mesylate treatment

Chu, S., Xu, H., Shah, N. P., Snyder, D., Forman, S. J., Sawyers, C. L., & Bhatia, R. (2004) · Blood · doi:10.1182/blood-2004-03-1114 · Cited by 208 · see citing works

hOCT 1 and resistance to imatinib

Crossman, L. C., Druker, B. J., & Deininger, M. W. (2005) · Blood · doi:10.1182/blood-2005-02-0694 · Cited by 207 · see citing works

Bcr-Abl Expression Levels Determine the Rate of Development of Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia

Barnes, D., Palaiologou, D., Panousopoulou, E., Schultheis, B. S., Yong, A. S. M., Wong, A., Pattacini, L., Goldman, J. M., & Melo, J. V. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0076 · Cited by 200 · see citing works

Kinase Domain Mutants of Bcr-Abl Exhibit Altered Transformation Potency, Kinase Activity, and Substrate Utilization, Irrespective of Sensitivity to Imatinib

Griswold, I. J., MacPartlin, M., Bumm, T. G. P., Goss, V. L., O’Hare, T., Lee, K. A., Corbin, A. S., Stoffregen, E. P., Smith, C., Johnson, K. J., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02202-05 · Cited by 199 · see citing works

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

Branford, S., Melo, J. V., & Hughes, T. P. (2009) · Blood · doi:10.1182/blood-2009-08-215939 · Cited by 197 · see citing works

Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial

Apperley, J. F., Cortes, J. E., Kim, D.-W., Roy, L., Roboz, G. J., Rosti, G., Bullorsky, E. O., Abruzzese, E., Hochhaus, A., Heim, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3339 · Cited by 194 · see citing works

Functional Activity of the OCT-1 Protein Is Predictive of Long-Term Outcome in Patients With Chronic-Phase Chronic Myeloid Leukemia Treated With Imatinib

White, D. L., Dang, P., Engler, J. R., Frede, A., Zrim, S., Osborn, M. P., Saunders, V. A., Manley, P. W., & Hughes, T. P. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.5819 · Cited by 185 · see citing works

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

Soverini, S., Colarossi, S., Gnani, A., Castagnetti, F., Rosti, G., Bosi, C., Paolini, S., Rondoni, M., Piccaluga, P. P., Palandri, F., et al. (2007) · Haematologica · doi:10.3324/haematol.10822 · Cited by 184 · see citing works

Activation of Src kinases p53/56lyn and p59hck by p210bcr/abl in myeloid cells.

Danhauser-riedl, S., Warmuth, M., Druker, B. J., Emmerich, B., & Hallek, M. J. (1996) · PubMed · Cited by 182 · see citing works

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Genes to Predict Response and Resistance to Imatinib Therapy in Chronic Myeloid Leukemia

Kim, D., Sriharsha, L., Xu, W., Kamel‐Reid, S., Liu, X., Siminovitch, K., Messner, H. A., & Lipton, J. H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0145 · Cited by 182 · see citing works

Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression

Khorashad, J. S., de Lavallade, H., Apperley, J. F., Milojković, D., Reid, A. G., Bua, M., Szydlo, R., Olavarría, E., Kaeda, J., Goldman, J. M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.9953 · Cited by 179 · see citing works

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors

Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Abruzzese, E., Paolini, S., Merante, S., Orlandi, E. M., Matteis, S. D., Gozzini, A., et al. (2009) · Blood · doi:10.1182/blood-2009-01-197186 · Cited by 174 · see citing works

Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia

Burchert, A., Müller, M. C., Kostrewa, P., Erben, P., Bostel, T., Liebler, S., Hehlmann, R., Neubauer, A., & Hochhaus, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.5075 · Cited by 174 · see citing works

Analysis of the Structural Basis of Specificity of Inhibition of the Abl Kinase by STI571

Corbin, A. S., Buchdunger, E., Furet, P., & Druker, B. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m111525200 · Cited by 165 · see citing works

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia

Bixby, D. L., & Talpaz, M. (2010) · Leukemia · doi:10.1038/leu.2010.238 · Cited by 162 · see citing works

Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy

Jabbour, E. J., Kantarjian, H. M., Jones, D. M., Shan, J., O'Brien, S. M., Reddy, N., Wierda, W. G., Faderl, S. H., Garcia‐Manero, G., Verstovšek, S., et al. (2008) · Blood · doi:10.1182/blood-2008-04-154344 · Cited by 154 · see citing works

Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors

Kantarjian, H. M., Cortes, J. E., Kim, D., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E. P., Kelly, V. M., et al. (2013) · Blood · doi:10.1182/blood-2013-07-513937 · Cited by 151 · see citing works

The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML

O'Dwyer, M. E., Mauro, M. J., Kurilik, G., Mori, M., Balleisen, S., Olson, S. B., Magenis, E., Capdeville, R., & Druker, B. J. (2002) · Blood · doi:10.1182/blood-2002-03-0777 · Cited by 145 · see citing works

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Kantaijian, H. (2007) · Blood · Cited by 143 · see citing works

Phase II study of low‐dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia

Oki, Y., Kantarjian, H. M., Gharibyan, V., Jones, D. M., O'Brien, S. M., Verstovšek, S., Cortes, J. E., Morris, G. M., Garcia‐Manero, G., & Issa, J. J. (2007) · Cancer · doi:10.1002/cncr.22470 · Cited by 136 · see citing works

Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation

Cortes, J. E., Lipton, J. H., Réa, D., Digumarti, R., Chuah, C. T. H., Nanda, N., Benichou, A., Craig, A. R., Michallet, M., Nicolini, F. E., et al. (2012) · Blood · doi:10.1182/blood-2012-03-415307 · Cited by 134 · see citing works

Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib

Marín, D., Hedgley, C. A., Clark, R. E., Apperley, J. F., Foroni, L., Milojković, D., Pocock, C., Goldman, J. M., & O’Brien, S. J. (2012) · Blood · doi:10.1182/blood-2012-01-407486 · Cited by 130 · see citing works

Loss of p53 impedes the antileukemic response to BCR-ABL inhibition

Wendel, H., de Stanchina, E., Cepero, E., Ray, S., Emig, M., Fridman, J. S., Veach, D. R., Bornmann, W. G., Clarkson, B. D., McCombie, W. R., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0602402103 · Cited by 124 · see citing works

Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells

Wu, J. Y., Meng, F., Lu, H. Y., Kong, L. Y., Bornmann, W. G., Peng, Z., Talpaz, M., & Donato, N. J. (2008) · Blood · doi:10.1182/blood-2007-08-109330 · Cited by 111 · see citing works

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Kantarjian, H. M., Larson, R. A., Guilhot, F., O’Brien, S. G., Mone, M. D., Rudoltz, M. S., Krahnke, T., Cortes, J. E., Druker, B. J., & for the International Randomized Study of Interferon and STI571 (IRIS) Investigators (2009) · Cancer · doi:10.1002/cncr.24066 · Cited by 111 · see citing works

Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib

Ernst, T., Erben, P., Muller, M. C., Paschka, P., Schenk, T., Hoffmann, J., Kreil, S., Rosée, P. G. L., Hehlmann, R., & Hochhaus, A. (2008) · Haematologica · doi:10.3324/haematol.11993 · Cited by 108 · see citing works

Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase

Alvarado, Y., Kantarjian, H. M., O'Brien, S. M., Faderl, S. H., Borthakur, G. M., Burger, J. A., Wierda, W. G., Garcia‐Manero, G., Shan, J., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24418 · Cited by 106 · see citing works

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009

Quintás‐Cardama, A., Kantarjian, H. M., & Cortes, J. E. (2009) · Cancer · doi:10.1002/cncr.24601 · Cited by 106 · see citing works

The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.

Zonder, J. A., Pemberton, P., Brandt, H., Mohamed, A. N., & Schiffer, C. A. (2003) · PubMed · Cited by 100 · see citing works

Characterization of cancer stem cells in chronic myeloid leukaemia

Jørgensen, H. G., & Holyoake, T. L. (2007) · Biochemical Society Transactions · doi:10.1042/bst0351347 · Cited by 91 · see citing works

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

José‐Eneriz, E. S., Agirre, X., Jiménez‐Velasco, A., Cordeu, L., Martín, V., Arqueros, V., Gárate, L., Fresquet, V. J., Cervantes, F., Martinez-Climent, J. A., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.04.005 · Cited by 90 · see citing works

Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate

Schoch, C., Haferlach, T., Kern, W., Schnittger, S., Berger, U., Hehlmann, R., Hiddemann, W., & Hochhaus, A. (2003) · Leukemia · doi:10.1038/sj.leu.2402813 · Cited by 88 · see citing works

In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib

Khorashad, J. S., Milojković, D., Mehta, P., Anand, M., Ghorashian, S., Reid, A. G., Melo, V. D., Babb, A., de Lavallade, H., Olavarría, E., et al. (2007) · Blood · doi:10.1182/blood-2007-06-096396 · Cited by 87 · see citing works

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

Tipping, A. J., Mahon, F., Zafirides, G., Lagarde, V., Goldman, J. M., & Melo, J. (2002) · Leukemia · doi:10.1038/sj.leu.2402775 · Cited by 87 · see citing works

Resistance to Imatinib: Mutations and Beyond

Rosée, P. G. L., & Deininger, M. W. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.06.005 · Cited by 86 · see citing works

Overexpression of P-glycoprotein in K562 cells does not confer resistance to the growth inhibitory effects of imatinib (STI571) in vitro

Ferrao, P. T., Frost, M. J., Siah, S.-P., & Ashman, L. K. (2003) · Blood · doi:10.1182/blood-2003-01-0083 · Cited by 85 · see citing works

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib

Sherbenou, D. W., Hantschel, O. D., Kaupe, I., Willis, S. G., Bumm, T. G. P., Turaga, L., Lange, T., Dao, K.-H. T., Press, R. D., Druker, B. J., et al. (2010) · Blood · doi:10.1182/blood-2008-10-183665 · Cited by 85 · see citing works

α1-Acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571

Jørgensen, H. G., Elliott, M. A., Allan, E. K., Carr, C. E., Holyoake, T. L., & Smith, K. D. (2002) · Blood · doi:10.1182/blood.v99.2.713 · Cited by 82 · see citing works

Laboratory Practice Guidelines for Detecting and Reporting BCR-ABL Drug Resistance Mutations in Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia

Jones, D. M., Kamel‐Reid, S., Bahler, D. W., Dong, H. Y., Elenitoba‐Johnson, K. S. J., Press, R. D., Quigley, N. B., Rothberg, P. G., Sabath, D., Viswanatha, D. S., et al. (2008) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2009.080095 · Cited by 81 · see citing works

Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells

Allan, E. K., Holyoake, T. L., Craig, A. R., & Jørgensen, H. G. (2011) · Leukemia · doi:10.1038/leu.2011.55 · Cited by 80 · see citing works

Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib

Sherbenou, D. W., Wong, M. J., Humayun, A., McGreevey, L. S., Harrell, P. M., Yang, R., Mauro, M. J., Heinrich, M. C., Press, R. D., Druker, B. J., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404554 · Cited by 78 · see citing works

Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

Jabbour, E. J., Kantarjian, H. M., O'Brien, S. M., Shan, J., Quintás‐Cardama, A., Garcia‐Manero, G., Rios, M. B., & Cortes, J. E. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0693 · Cited by 78 · see citing works

Omacetaxine as an Anticancer Therapeutic: What is Old is New Again

Wetzler, M., & Segal, D. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795049778 · Cited by 76 · see citing works

Bcr-Abl-Independent Imatinib-Resistant K562 Cells Show Aberrant Protein Acetylation and Increased Sensitivity to Histone Deacetylase Inhibitors

Lee, S. M., Bae, J. H., Kim, M. J., Lee, H. S., Lee, M. K., Chung, B., Kim, D. W., Kang, C., & Kim, S. H. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.124461 · Cited by 73 · see citing works

The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.

Wang, L., Knight, K., Lucas, C., & Clark, R. E. (2006) · PubMed · Cited by 61 · see citing works

Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways

Tang, C., Schafranek, L., Watkins, D. B., Parker, W. T., Moore, S., Prime, J. A., White, D. L., & Hughes, T. P. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2011.591013 · Cited by 59 · see citing works

BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation

Alikian, M., Gerrard, G., Subramanian, P. G., Mudge, K., Foskett, P., Khorashad, J. S., Lim, A. C., Marín, D., Milojković, D., Reid, A. G., et al. (2011) · American Journal of Hematology · doi:10.1002/ajh.22272 · Cited by 58 · see citing works

Phase 1 study of INNO‐406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome‐positive leukemias after imatinib resistance or intolerance

Kantarjian, H. M., Coutre, P. D. L., Cortes, J. E., Pinilla-Ibarz, J. A., Nagler, A., Hochhaus, A., Kimura, S. H., & Ottmann, O. G. (2010) · Cancer · doi:10.1002/cncr.25079 · Cited by 57 · see citing works

Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice

Branford, S. (2007) · Hematology · doi:10.1182/asheducation-2007.1.376 · Cited by 56 · see citing works

Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease Progression

Ernst, T., & Hochhaus, A. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.11.002 · Cited by 56 · see citing works

Comparative In Vitro Cellular Data Alone Are Insufficient to Predict Clinical Responses and Guide the Choice of BCR-ABL Inhibitor for Treating Imatinib-Resistant Chronic Myeloid Leukemia

Laneuville, P., DiLea, C., Yin, O. Q. P., Woodman, R. C., Mestan, J., & Manley, P. W. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.4945 · Cited by 54 · see citing works

A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial

Cortes, J. E., Kim, D., Pinilla-Ibarz, J. A., le Coutre, P., Paquette, R. L., Chuah, C. T. H., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2012) · Blood · doi:10.1182/blood.v120.21.163.163 · Cited by 54 · see citing works

PHA-739358, an Aurora Kinase Inhibitor, Induces Clinical Responses in Chronic Myeloid Leukemia Harboring T315I Mutations of BCR-ABL.

PAQUETTE, R. L., Shah, N. P., Sawyers, C. L., Martinelli, G., Nicoll, J. M., Chalukya, M., Rocchetti, M., Fiocchi, C., Comis, S., Capolongo, L., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1030.1030 · Cited by 53 · see citing works

Danusertib (formerly PHA-739358) – A Novel Combined Pan-Aurora Kinases and Third Generation Bcr-Abl Tyrosine Kinase Inhibitor

Gontarewicz, A., & Brümmendorf, T. H. (2009) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-642-01222-8_14 · Cited by 50 · see citing works

Preliminary Clinical Activity in a Phase I Trial of the BCR-ABL/IGF- 1R/Aurora Kinase Inhibitor XL228 in Patients with Ph++ Leukemias with Either Failure to Multiple TKI Therapies or with T315I Mutation

Cortes, J. E., PAQUETTE, R. L., Talpaz, M., Pinilla, J., Asatiani, E., Wetzler, M., Lipton, J. H., Kasap, C., Bui, L. A., Clary, D. O., et al. (2008) · Blood · doi:10.1182/blood.v112.11.3232.3232 · Cited by 50 · see citing works

Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment

Galimberti, S., Cervetti, G., Guerrini, F., Testi, R., Pacini, S., Fazzi, R., Simi, P., & Petrini, M. (2005) · Cancer Genetics and Cytogenetics · doi:10.1016/j.cancergencyto.2005.01.015 · Cited by 49 · see citing works

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla-Ibarz, J. A., Larson, R. A., Gattermann, N., Ottmann, O. G., Hochhaus, A., Radich, J. P., Saglio, G. N., et al. (2009) · Blood · doi:10.1182/blood.v114.22.1129.1129 · Cited by 49 · see citing works

NCCN Task Force Report: Tyrosine Kinase Inhibitor Therapy Selection in the Management of Patients With Chronic Myelogenous Leukemia

O'Brien, S. M., Berman, E., Moore, J. O., Pinilla-Ibarz, J. A., Radich, J. P., Shami, P. J., Smith, B. D., Snyder, D., Sundar, H. M., Talpaz, M., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0125 · Cited by 48 · see citing works

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia

Kim, T. D., Türkmen, S., Schwarz, M., Koca, G., Nogai, H., Bommer, C., Dörken, B., Daniel, P., & le Coutre, P. (2009) · Haematologica · doi:10.3324/haematol.2009.014712 · Cited by 45 · see citing works

Danusertib Hydrochloride (PHA-739358), a Multi-Kinase Aurora Inhibitor, Elicits Clinical Benefit in Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia .

Cortes, J. E., Dombret, H., Schafhausen, P., Brümmendorf, T. H., Boissel, N., Latini, F., Capolongo, L., Laffranchi, B. L., & Comis, S. (2009) · Blood · doi:10.1182/blood.v114.22.864.864 · Cited by 43 · see citing works

Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL

Soverini, S., Martinelli, G., Colarossi, S., Gnani, A., Rondoni, M., Castagnetti, F., Paolini, S., Rosti, G., & Baccarani, M. (2007) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70078-5 · Cited by 42 · see citing works

Homoharringtonine for the treatment of chronic myelogenous leukemia

Quintás‐Cardama, A., & Cortes, J. E. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.6.1029 · Cited by 40 · see citing works

Diagnosis and management of chronic myeloid leukemia

Kantarjian, H. M., Cortes, J. E., Guilhot, F., Hochhaus, A., Baccarani, M., & Lokey, L. (2007) · Cancer · doi:10.1002/cncr.22523 · Cited by 39 · see citing works

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patients Who Harbor the Bcr- Abl T315I Mutation–Results of An Ongoing Multicenter Phase 2/3 Study.

Cortes, J. E., Khoury, H. J., Nicolini, F. E., Corm, S., Lipton, J. H., Jones, D. M., Hochhaus, A., Craig, A. R., Benichou, A., Humphriss, E., et al. (2009) · Blood · doi:10.1182/blood.v114.22.644.644 · Cited by 39 · see citing works

A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib

Ernst, T., Gruber, F., Pelz-Ackermann, O., Maier, J., Pfirrmann, M., Müller, M. C., Mikkola, I., Porkka, K., Niederwieser, D. W., Hochhaus, A., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.006981 · Cited by 37 · see citing works

Recent developments in drug resistance mechanism in chronic myeloid leukemia: a review

Vaidya, S., Ghosh, K., & Vundinti, B. R. (2011) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2011.01689.x · Cited by 36 · see citing works

Monitoring Response and Resistance to Treatment in Chronic Myeloid Leukemia

Assouline, S. E., & Lipton, J. H. (2011) · Current Oncology · doi:10.3747/co.v18i2.391 · Cited by 35 · see citing works

Phase I and pharmacodynamic trial of AT9283, an aurora kinase inhibitor, in patients with refractory leukemia

Foran, J. M., Ravandi, F., O'Brien, S. M., Borthakur, G. M., Rios, M. B., Boone, P. A., Worrell, J., Mallett, K., Squires, M. S., Fazal, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.2518 · Cited by 35 · see citing works

Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data

Saglio, G. N., Kantarjian, H. M., Shah, N. P., Jabbour, E. J., Quintás‐Cardama, A., Steegmann, J. L., Boqué, C., Chuah, C. T. H., Pavlovsky, C., Mayer, J., et al. (2012) · Blood · doi:10.1182/blood.v120.21.1675.1675 · Cited by 34 · see citing works

Stem cell and kinase activity‐independent pathway in resistance of leukaemia to BCR‐ABL kinase inhibitors

Li, S., & Li, D. (2007) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2007.00108.x · Cited by 33 · see citing works

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Based On Early Molecular Response and Factors Associated with Early Response: 4-Year Follow-up Data From Enestnd (Evaluating Nilotinib Efficacy and Safety in Clinical Trials Newly Diagnosed Patients)

Hochhaus, A., Hughes, T. P., Saglio, G. N., Guilhot, F., Al‐Ali, H. K., Rosti, G., Nakaseko, C., Souza, C. A. D., Kemp, C. N., Fan, X., et al. (2012) · Blood · doi:10.1182/blood.v120.21.167.167 · Cited by 33 · see citing works

A Phase I Dose Escalation Study of KW-2449, An Oral Multi-Kinase Inhibitor against FLT3, Abl, FGFR1 and Aurora in Patients with Relapsed/Refractory AML, ALL and MDS or Resistant/Intolerant CML

Cortes, J. E., Roboz, G. J., Kantarjian, H. M., Feldman, E. J., Karp, J. E., Pratz, K. W., Rao, N. S., Akinaga, S., & Levis, M. J. (2008) · Blood · doi:10.1182/blood.v112.11.2967.2967 · Cited by 32 · see citing works

Safety and Efficacy of Subcutaneous-Administered Omacetaxine Mepesuccinate in Chronic Myeloid Leukemia (CML) Patients Who Are Resistant or Intolerant to Two or More Tyrosine Kinase Inhibitors – Results of A Multicenter Phase 2/3 Study.

Cortes, J. E., Raghunadharao, D., Parikh, P. M., Wetzler, M., Lipton, J. H., Jones, D. M., Hochhaus, A., Kantarjian, H. M., Craig, A. R., Benichou, A., et al. (2009) · Blood · doi:10.1182/blood.v114.22.861.861 · Cited by 32 · see citing works

Successful treatment of a chronic-phase T-315I-mutated chronic myelogenous leukemia patient with a combination of imatinib and interferon-alfa

Itonaga, H., Tsushima, H., Hata, T., Matsuo, E., Imanishi, D., Imaizumi, Y., Kawaguchi, Y., Fukushima, T., Doi, Y., Mori, S., et al. (2012) · International Journal of Hematology · doi:10.1007/s12185-012-1005-1 · Cited by 27 · see citing works

Mutational analysis in chronic myeloid leukemia: when and what to do?

Branford, S., & Hughes, T. P. (2011) · Current Opinion in Hematology · doi:10.1097/moh.0b013e32834399ef · Cited by 27 · see citing works

Challenges for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors

Oyekunle, A. A., Klyuchnikov, E., Ocheni, S., Kröger, N. M., Zander, A. R., Baccarani, M., & Bacher, U. (2011) · Acta Haematologica · doi:10.1159/000323662 · Cited by 25 · see citing works

Can we afford to let sleeping dogs lie?

Deininger, M. W., & Holyoake, T. L. (2005) · Blood · doi:10.1182/blood-2004-12-4764 · Cited by 22 · see citing works

The Clinical Significance of Achieving Different Levels of Cytogenetic Response in Patients With Chronic Phase Chronic Myeloid Leukemia After Failure to Front-Line Therapy: Is Complete Cytogenetic Response the Only Desirable Endpoint?

Cortes, J. E., Quintás‐Cardama, A., Jabbour, E. J., O'Brien, S. M., Verstovšek, S., Borthakur, G. M., Ravandi, F., Garcia‐Manero, G., Burton, E. M., Shan, J., et al. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.06.009 · Cited by 21 · see citing works

Nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) with imatinib (IM) resistance or intolerance: Longer follow-up results of a phase II study

Kantarjian, H. M., Giles, F. J., Bhalla, K. N., Pinilla, J., Larson, R. A., Gattermann, N., Ottmann, O. G., Gallagher, N. J., Baccarani, M., & LeCoutre, P. D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.7029 · Cited by 21 · see citing works

BCR-ABL mutation testing to predict response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia

Terasawa, T., Dahabreh, I. J., & Trikalinos, T. A. (2010) · PLoS Currents · doi:10.1371/currents.rrn1204 · Cited by 20 · see citing works

Targeting Drug-Resistant CML and Ph+-ALL with the Spectrum Selective Protein Kinase Inhibitor XL228.

Shah, N. P., Kasap, C., PAQUETTE, R. L., Cortes, J. E., Pinilla, J., Talpaz, M., Bui, L. A., & Clary, D. O. (2007) · Blood · doi:10.1182/blood.v110.11.474.474 · Cited by 20 · see citing works

Chromosome 20q Deletion

Sun, J., Yin, C. C., Cui, W., Chen, S. S., Medeiros, L. J., & Lu, G. G. (2011) · American Journal of Clinical Pathology · doi:10.1309/ajcpqfsc9zjnmaz6 · Cited by 19 · see citing works

Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone

Nicolini, F. E., Hayette, S., Legros, L., Rousselot, P. H., Maloisel, F., Tulliez, M., Guerci‐Bresler, A., Charbonnier, A., Prébet, T., Huguet, F., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.04.010 · Cited by 16 · see citing works

BCR-ABL isoforms associated with intrinsic or acquired resistance to imatinib: more heterogeneous than just ABL kinase domain point mutations?

Gruber, F., Lundán, T., Goll, R., Silye, A., Mikkola, I., Rekvig, O. P., Knuutila, S., Remes, K., Gedde‐Dahl, T., Porkka, K., et al. (2011) · Medical Oncology · doi:10.1007/s12032-010-9781-z · Cited by 14 · see citing works

Dasatinib Combined with Interferon-alfa Induces a Complete Cytogenetic Response and Major Molecular Response in a Patient with Chronic Myelogenous Leukemia Harboring the T315I BCR-ABL1 Mutation

Cornelison, A. M., Welch, M.-A., Koller, C. A., & Jabbour, E. J. (2011) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2011.03.032 · Cited by 14 · see citing works

A phase II study of nilotinib administered to patients with imatinib resistant or intolerant chronic myelogenous leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast crisis (BC) who also failed dasatinib

Giles, F. J., le Coutre, P., Bhalla, K. N., Rosti, G., Ossenkoppele, G. J., Alimena, G., Weitzman, A., Zheng, M., & Kantarjian, H. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7038 · Cited by 14 · see citing works

Undetectable molecular residual disease after omacetaxine and nilotinib combination therapy in an imatinib‐resistant chronic myeloid leukaemia patient harbouring the BCR‐ABL1 T315I gatekeeper mutation

Coudé, M.-M., Luycx, O., Cariou, M., Maarek, O., Dombret, H., Cayuela, J., & Réa, D. (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2011.09016.x · Cited by 13 · see citing works

Efficacy and Safety of Ponatinib in Patients with Accelerated Phase or Blast Phase Chronic Myeloid Leukemia (AP-CML or BP-CML) or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL): 12-Month Follow-up of the PACE Trial

Kantarjian, H. M., Kim, D., Pinilla-Ibarz, J. A., le Coutre, P., PAQUETTE, R. L., Chuah, C. T. H., Nicolini, F. E., Apperley, J. F., Khoury, H. J., Talpaz, M., et al. (2012) · Blood · doi:10.1182/blood.v120.21.915.915 · Cited by 12 · see citing works

A Phase 2 study of the Combination of Omacetaxine and Imatinib in the Treatment of Patients with Chronic Myeloid Leukemia (CML) in Advanced Stages or After Failure to Imatinib.

Ayoubi, M., Kantarjian, H. M., Wierda, W. G., Ferrajoli, A., Hiteshew, J., Estrov, Z. E., & Cortes, J. E. (2009) · Blood · doi:10.1182/blood.v114.22.2193.2193 · Cited by 10 · see citing works

The Predictive Value of Early Molecular Response in Chronic Phase CML Patients Treated with Dasatinib First Line Therapy

Marin, D., Hedgley, C. A., Clark, R. E., Apperley, J. F., Foroni, L., Milojković, D., Pocock, C., Goldman, J. M., & O’Brien, S. J. (2011) · Blood · doi:10.1182/blood.v118.21.785.785 · Cited by 8 · see citing works

Pooled safety analysis of omacetaxine mepesuccinate in patients with chronic myeloid leukemia (CML) resistant to tyrosine-kinase inhibitors (TKIs).

Wetzler, M., Kantarjian, H. M., Nicolini, F. E., Lipton, J. H., Akard, L. P., Baccarani, M., Craig, A., Brown, P. D. N., & Cortes, J. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6604 · Cited by 8 · see citing works

Omacetaxine mepesuccinate in chronic-phase chronic myeloid leukemia (CML) in patients resistant, intolerant, or both to two or more tyrosine-kinase inhibitors (TKIs).

Akard, L. P., Kantarjian, H. M., Nicolini, F. E., Wetzler, M., Lipton, J. H., Baccarani, M., Craig, A., Nanda, N., Brown, P. D. N., & Cortes, J. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6596 · Cited by 8 · see citing works

Subcutaneous omacetaxine mepesuccinate in patients with chronic phase (CP) or accelerated phase (AP) chronic myeloid leukemia (CML) resistant/intolerant to two or three approved tyrosine-kinase inhibitors (TKIs).

Nicolini, F. E., Lipton, J. H., Kantarjian, H. M., Wetzler, M., Akard, L. P., Baccarani, M., Craig, A., Nanda, N., Brown, P. D. N., & Cortes, J. E. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.6513 · Cited by 8 · see citing works

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

Kantarjian, H. M., Larson, R. A., Guilhot, F., O’Brien, S. G., Mone, M. D., Rudoltz, M. S., Krahnke, T., Cortes, J. E., & Druker, B. J. (2010) · Cancer · doi:10.1002/cncr.25358 · Cited by 7 · see citing works

Molecular Monitoring of BCR-ABL Transcripts—Standardization Needed to Properly Use, and Further Investigate the Value of, a Critical Surrogate Marker for Success in Therapy of Chronic Myeloid Leukemia

Giles, F. J. (2011) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2011.07.2.138 · Cited by 5 · see citing works

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Resistance or Intolerance to Imatinib: 36-Month Minimum Follow-up Update

Cortes, J. E., Kantarjian, H. M., Kim, D., Turkina, A., Shen, Z., Khoury, H. J., Brümmendorf, T. H., Schafhausen, P., Vellenga, E., Pasqüini, R., et al. (2012) · Blood · doi:10.1182/blood.v120.21.3779.3779 · Cited by 4 · see citing works

In Early-Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib, Resistance Is Rarely Mediated by Abl Kinase Domain Mutations.

Soverini, S., Gnani, A., Colarossi, S., Castagnetti, F., Abruzzese, E., Merante, S., Breccia, M., Capucci, A., Specchia, G., Radaelli, F., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1934.1934 · Cited by 4 · see citing works

Real-Life Rates of Disease Monitoring in Clinical Practice in Europe: The “Unmet Needs in CML and Ph+ALL” (UNIC) Study.

Morra, E., Michallet, M., Steegmann, J. L., Costa, D. M., Ossenkoppele, G. J., Verhoef, G. E. G., Kühr, T., Björeman, M., Paga, C., Cohen, C., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1959.1959 · Cited by 4 · see citing works

Bosutinib As Therapy for Chronic Phase Chronic Myeloid Leukemia Following Failure with Imatinib Plus Dasatinib and/or Nilotinib: 24-Month Minimum Follow-up Update

Khoury, H. J., Gambacorti-Passerini, C. B., Kantarjian, H. M., Kim, D.-W., Marín, D., Dorlhiac‐Llacer, P. E., Zaritskey, A. Y., Navarro, J. R., Bullorsky, E. O., Assouline, S. E., et al. (2012) · Blood · doi:10.1182/blood.v120.21.3785.3785 · Cited by 4 · see citing works

Clinical Relevance of a Pharmacogenetic Approach Using Multiple Candidate Gene Polymorphisms To Predict Response and Resistance to Imatinib Mesylate Therapy in Chronic Myeloid Leukemia.

Kim, D. H., Sriharsha, L., Xu, W., Kamel‐Reid, S., Liu, X., Siminovitch, K., Messner, H. A., & Lipton, J. H. (2007) · Blood · doi:10.1182/blood.v110.11.737.737 · Cited by 3 · see citing works

Bosutinib Safety Profile and Management of Toxicities in Leukemia Patients with Resistance or Intolerance to Imatinib and Other Tyrosine Kinase Inhibitors

Kantarjian, H. M., Cortes, J. E., Kim, D., Khoury, H. J., Brümmendorf, T. H., Porkka, K., Martinelli, G., Durrant, S., Leip, E. P., Besson, N., et al. (2011) · Blood · doi:10.1182/blood.v118.21.2760.2760 · Cited by 3 · see citing works

Functional Characterization of ABCG2 Polymorphisms and Their Influence on Tyrosine Kinase Inhibitor Effects in Chronic Myeloid Leukemia Cells,

Skoglund, K., Moreno, S. B., Jönsson, J., & Gréen, H. (2011) · Blood · doi:10.1182/blood.v118.21.3495.3495 · Cited by 2 · see citing works

Blast Phase Chronic Myeloid Leukemia: A Pooled Analysis of Subcutaneous Omacetaxine Mepesuccinate in Treatment-Resistant Patients

Khoury, H. J., Cortes, J. E., Wetzler, M., Lipton, J. H., Baccarani, M., Douer, D., Craig, A., Kantarjian, H. M., & Akard, L. P. (2012) · Blood · doi:10.1182/blood.v120.21.3753.3753 · Cited by 1 · see citing works

Partially or Fully BCR-ABL Independent Mechanisms of in Vitro Resistance to Ponatinib

Yu, Q., Eiring, A. M., Zabriskie, M. S., Khorashad, J. S., Anderson, D. J., Bryant, J. A., Loriaux, M., Tyner, J. W., O’Hare, T., & Deininger, M. W. (2011) · Blood · doi:10.1182/blood.v118.21.2481.2481 · Cited by 1 · see citing works

Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.

Kim, D., Kim, D., Kim, S., Goh, H., Pane, F., Hughes, T. P., Radich, J. P., Lin, P., Saglio, G. N., Branford, S., et al. (2010) · Blood · doi:10.1182/blood.v116.21.3441.3441 · Cited by 1 · see citing works

Drug resistance and combating drug resistance in cancer

Wang, X., Zhang, H., & Chen, X. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.10 · Cited by 1,105 · see citing works

Taxanes in cancer treatment: Activity, chemoresistance and its overcoming

Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 390 · see citing works

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Valent, P., Hadzijusufovic, E., Schernthaner, G.-H., Wolf, D. G. F., Réa, D., & le Coutre, P. (2014) · Blood · doi:10.1182/blood-2014-09-594432 · Cited by 283 · see citing works

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure

Pagliarini, R. A., Shao, W., & Sellers, W. R. (2015) · EMBO Reports · doi:10.15252/embr.201439949 · Cited by 255 · see citing works

Resisting Resistance: Targeted Therapies in Lung Cancer

Lin, J. J., & Shaw, A. T. (2016) · Trends in cancer · doi:10.1016/j.trecan.2016.05.010 · Cited by 232 · see citing works

A protective effect after clearance of orthotopic rat hepatocellular carcinoma by nanosecond pulsed electric fields

Chen, R., Sain, N. M., Harlow, K. T., Chen, Y.-J., Shires, P. K., Heller, R. F., & Beebe, S. J. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.07.006 · Cited by 88 · see citing works

Risk factors and mechanisms contributing to TKI-induced vascular events in patients with CML

Valent, P., Hadzijusufovic, E., Hoermann, G., Füreder, W., Schernthaner, G.-H., Sperr, W. R., Kirchmair, R., & Wolf, D. G. F. (2017) · Leukemia Research · doi:10.1016/j.leukres.2017.05.008 · Cited by 73 · see citing works

The impact of the BCR-ABL oncogene in the pathology and treatment of chronic myeloid leukemia

El‐Tanani, M., Nsairat, H., Matalka, I. I., Lee, Y. F., Rizzo, M., Aljabali, A. A. A., Mishra, V. K., Mishra, Y., Hromić‐Jahjefendić, A., & Tambuwala, M. M. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155161 · Cited by 62 · see citing works

Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options

Sundaram, D. N. M., Jiang, X., Brandwein, J. M., Valencia‐Serna, J., Remant, K. C. B., & Uludağ, H. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.05.007 · Cited by 61 · see citing works

Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY

Hehlmann, R., Cortes, J. E., Zyczynski, T. M., Gambacorti-Passerini, C. B., Goldberg, S. L., Mauro, M. J., Michallet, M., Simonsson, B., Williams, L. A., Gajavelli, S., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25306 · Cited by 56 · see citing works

CBP/catenin antagonist safely eliminates drug-resistant leukemia-initiating cells

Zhao, Y., Masiello, D., McMillian, M., Nguyen, C., Wu, Y., Melendez, E., Smbatyan, G., Kida, A., He, Y. J., Teo, J.-L., et al. (2015) · Oncogene · doi:10.1038/onc.2015.438 · Cited by 52 · see citing works

Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase

Hoemberger, M., Pitsawong, W., & Kern, D. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1919221117 · Cited by 50 · see citing works

Nanotechnology of Tyrosine Kinase Inhibitors in Cancer Therapy: A Perspective

Russo, E., Spallarossa, A., Tasso, B., Villa, C., & Brullo, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126538 · Cited by 47 · see citing works

Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases**

Shekhar, M., Smith, Z., Seeliger, M. A., & Tiwary, P. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202200983 · Cited by 46 · see citing works

Adaptive phenotypic modulations lead to therapy resistance in chronic myeloid leukemia cells

Baykal, S., Açıkgöz, E., Yavuz, A. S., Geyik, Ö. G., Ateş, H., Sezerman, O. U., Özsan, G. H., & Yüce, Z. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229104 · Cited by 44 · see citing works

Induction of Heme Oxygenase-1 by Na+-H+ Exchanger 1 Protein Plays a Crucial Role in Imatinib-resistant Chronic Myeloid Leukemia Cells

Ma, D., Fang, Q., Wang, P., Gao, R., Wu, W., Lu, T., Cao, L., Hu, X., & Wang, J. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.626960 · Cited by 43 · see citing works

Drug Resistance and its Clinical Circumvention

Moscow, J. A., Cowan, K. H., & Sikic, B. I. (2017) · Holland‐Frei Cancer Medicine · doi:10.1002/9781119000822.hfcm063 · Cited by 43 · see citing works

Sensitization of Chemo-Resistant Human Chronic Myeloid Leukemia Stem-Like Cells to Hsp90 Inhibitor by SIRT1 Inhibition

Kim, H.-B., Lee, S.-H., Um, J., Kim, M., Hyun, S.-K., Gong, E. J., Oh, W. K., Kang, C., & Kim, S. (2015) · International Journal of Biological Sciences · doi:10.7150/ijbs.10896 · Cited by 42 · see citing works

Asciminib and ponatinib exert synergistic anti-neoplastic effects on CML cells expressing BCR-ABL1 T315I-compound mutations.

Gleixner, K. V., Filik, Y., Berger, D., Schewzik, C., Stefanzl, G., Sadovnik, I., Degenfeld‐Schonburg, L., Eisenwort, G., Schneeweiss‐Gleixner, M., Byrgazov, K., et al. (2021) · PubMed Central · Cited by 38 · see citing works

Network biology and artificial intelligence drive the understanding of the multidrug resistance phenotype in cancer

Bueschbell, B., Caniceiro, A. B., Suzano, P. M. S., Machuqueiro, M., Rosário‐Ferreira, N., & Moreira, I. S. (2022) · Drug Resistance Updates · doi:10.1016/j.drup.2022.100811 · Cited by 37 · see citing works

HDAC6—An Emerging Target Against Chronic Myeloid Leukemia?

Losson, H., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2020) · Cancers · doi:10.3390/cancers12020318 · Cited by 32 · see citing works

Self-enhanced luminol-based electrochemiluminescent hydrogels: An ultrasensitive biosensing platform for fusion gene analysis coupled with target-initiated DNAzyme motor

Duan, Y., Song, Y., Fan, N., Yao, Y., Deng, S., Ding, S., Shen, B., & Yin, Q. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113784 · Cited by 30 · see citing works

Resveratrol induces apoptosis of leukemia cell line K562 by modulation of sphingosine kinase-1 pathway.

Tian, H., & Yu, Z. (2015) · PubMed Central · Cited by 29 · see citing works

Update on emerging treatments for chronic myeloid leukemia

Fava, C., Morotti, A., Dogliotti, I., Saglio, G. N., & Rege‐Cambrin, G. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1031217 · Cited by 26 · see citing works

Pyruvate anaplerosis is a targetable vulnerability in persistent leukaemic stem cells

Rattigan, K. M., Brabcová, Z., Sarnello, D., Zarou, M. M., Roy, K., Kwan, R. S.-Y., de Beauchamp, L., Dawson, A., Ianniciello, A., Khalaf, A., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40222-z · Cited by 26 · see citing works

Multiomic Profiling of Tyrosine Kinase Inhibitor-Resistant K562 Cells Suggests Metabolic Reprogramming To Promote Cell Survival

Noel, B. M., Ouellette, S. B., Marholz, L., Dickey, D., Navis, C., Yang, T.-Y., Nguyen, V., Parker, S. J., Bernlohr, D., Sachs, Z., et al. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00028 · Cited by 24 · see citing works

Hsp90 Inhibitors for the Treatment of Chronic Myeloid Leukemia

Khajapeer, K. V., & Rajasekaran, B. (2015) · Leukemia Research and Treatment · doi:10.1155/2015/757694 · Cited by 24 · see citing works

MicroRNA-153-3p enhances the sensitivity of chronic myeloid leukemia cells to imatinib by inhibiting B-cell lymphoma-2-mediated autophagy

Li, Y., Tang, J., Chen, X.-Y., Luo, B., Liang, G.-H., Qu, Q., & Lu, Z. (2020) · Human Cell · doi:10.1007/s13577-020-00367-1 · Cited by 24 · see citing works

Resveratrol induces apoptosis in K562 cells via the regulation of mitochondrial signaling pathways.

Wang, B., Liu, J., & Gong, Z. (2015) · PubMed · Cited by 22 · see citing works

Just caring: Assessing the ethical and economic costs of personalized medicine

Fleck, L. M. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2013.09.013 · Cited by 20 · see citing works

BIRC6 mediates imatinib resistance independently of Mcl-1

Okumu, D. O., East, M. P., Levine, M., Herring, L. E., Zhang, R. J., Gilbert, T. S. K., Litchfield, D. W., Zhang, Y., & Graves, L. M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177871 · Cited by 20 · see citing works

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML

Schneeweiss‐Gleixner, M., Byrgazov, K., Stefanzl, G., Berger, D., Eisenwort, G., Lucini, C. B., Herndlhofer, S., Preuner, S., Obrová, K., Pušić, P., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.11.004 · Cited by 20 · see citing works

PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β

Fan, R.-F., Lu, Y., Fang, Z., Guo, X., Chen, Y., Xu, Y., Lei, Y.-M., Liu, K.-F., Lin, D.-J., Liu, L., et al. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7215 · Cited by 19 · see citing works

CBP/Catenin antagonists: Targeting LSCs’ Achilles heel

Kim, Y., Gang, E., & Kahn, M. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.010 · Cited by 18 · see citing works

Increasing economic burden of tyrosine kinase inhibitor treatment failure by line of therapy in chronic myeloid leukemia

McGarry, L. J., Chen, Y. J., Divino, V. M., Pokras, S., Taylor, C. R., Munakata, J., Nieset, C., Huang, H., Jabbour, E. J., & Malone, D. C. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1120189 · Cited by 17 · see citing works

1,4-Naphthoquinone (CNN1) Induces Apoptosis through DNA Damage and Promotes Upregulation of H2AFX in Leukemia Multidrug Resistant Cell Line

Portilho, A. J. D. S., da Silva, E. L., Bezerra, E. C. A., Gomes, C. B. D. S. M. R., Ferreira, V. F., de Moraes, M. E. A., da Rocha, D. R., Burbano, R. M. R., Moreira-Nunes, C. A., & Montenegro, R. C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158105 · Cited by 17 · see citing works

Dose Justification for Asciminib in Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia with and Without the T315I Mutation

Combes, F. P., Sy, S. K. B., Li, Y. F., Lorenzo, S., Dasgupta, K., Kapoor, S., Hoch, M., & Ho, Y. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01411-1 · Cited by 16 · see citing works

Characteristics ofBCR-ABLkinase domain mutations in chronic myeloid leukemia from India: not just missense mutations but insertions and deletions are also associated with TKI resistance

Patkar, N. V., Ghodke, K., Joshi, S., Chaudhary, S., Mascerhenas, R., Dusseja, S., Mahadik, S., Gaware, S., Tembhare, P. R., Gujral, S., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1157868 · Cited by 16 · see citing works

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escalation study

Martínez‐López, J., Mustjoki, S. M., Porkka, K., Klisovic, R. B., Wolf, D. G. F., Busque, L., Hernández‐Boluda, J. C., Swanink, R., Martin‐Regueira, P., & Lipton, J. H. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1889536 · Cited by 15 · see citing works

Identification of key microRNAs as predictive biomarkers of Nilotinib response in chronic myeloid leukemia: a sub-analysis of the ENESTxtnd clinical trial

Yen, R., Grasedieck, S., Wu, A., Lin, H., Su, J., Rothe, K., Nakamoto, H., Forrest, D. L., Eaves, C. J., & Jiang, X. (2022) · Leukemia · doi:10.1038/s41375-022-01680-4 · Cited by 15 · see citing works

Extramedullary relapse of acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation treated by CAR T-cell therapy: a case report

Wang, D., Shi, R. H., Wang, Q., & Li, J. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s164430 · Cited by 14 · see citing works

Analogs, formulations and derivatives of imatinib: a patent review

Musumeci, F., Schenone, S., Grossi, G., Brullo, C., & Sanna, M. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1089233 · Cited by 14 · see citing works

Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia

Knopf, K., Divino, V. M., McGarry, L. J., Chen, Y. J., Pokras, S., Munakata, J., Taylor, C. R., Ng, D., Nieset, C., & Huang, H. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.07.647 · Cited by 13 · see citing works

The Role of Pharmacogenomics in Individualized Medicine

zu Schwabedissen, H. E. M. (2015) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-3-319-11719-5_7 · Cited by 12 · see citing works

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review

Morozova, Е. V., Vlasova, Y. Y., Pryanishnikova, M. V., Lepik, K. V., & Afanasyev, B. V. (2015) · Biomarker Insights · doi:10.4137/bmi.s22438 · Cited by 12 · see citing works

Multidrug resistance in chronic myeloid leukemia

Yazıcı, M. Ü., Kiraz, Y., Kacı, F. N., Özcan, M. A., & Baran, Y. (2014) · TURKISH JOURNAL OF BIOLOGY · doi:10.3906/biy-1405-21 · Cited by 11 · see citing works

ZFX Facilitates Cell Proliferation and Imatinib Resistance in Chronic Myeloid Leukemia Cells

Wu, J., Wei, B., Wang, Q., Ding, Y., Deng, Z.-K., Lü, X., & Li, Y. (2016) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-016-0725-x · Cited by 11 · see citing works

Should Vascular Effects of Newer Treatments be Addressed More Completely?

Yang, E. H., Watson, K. E., & Herrmann, J. (2015) · Future Oncology · doi:10.2217/fon.15.119 · Cited by 11 · see citing works

Verbascoside potentiates the effect of tyrosine kinase inhibitors on the induction of apoptosis and oxidative stress via the Abl-mediated MAPK signalling pathway in chronic myeloid leukaemia

Çağlıyan, G. A., Çört, A., Kılıç-Toprak, E., & Altıntaş, F. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11441 · Cited by 10 · see citing works

EphB4/ephrinB2 Contributes to Imatinib Resistance in Chronic Myeloid Leukemia Involved in Cytoskeletal Proteins

Li, L., Xu, N., Zhang, J., Xu, L., Zhou, X., Huang, B.-T., Li, Y., & Liu, X. (2016) · International Journal of Medical Sciences · doi:10.7150/ijms.14989 · Cited by 10 · see citing works

Homoharringtonine enhances the effect of imatinib on chronic myelogenous leukemia cells by downregulating ZFX

Wu, J., Wei, B., Shi, Y., Lü, X., Ding, Y., Wang, C., & Li, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10539 · Cited by 10 · see citing works

Electronic and structural study of T315I mutated form in DFG-out conformation of BCR-ABL inhibitors

Pereira, W. A., Nascimento, É. C. M., & Martins, J. B. L. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1935320 · Cited by 9 · see citing works

Prevalence of BCR-ABL T315I Mutation in Different Chronic Myeloid Leukemia patients Categories

Khair, H. E., Moha, B. A., Nour, B. Y., & Waggia, H. A. (2022) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2022.175.181 · Cited by 9 · see citing works

Colorimetric determination of BCR/ABL fusion genes using a nanocomposite consisting of Au@Pt nanoparticles covered with a PAMAM dendrimer and acting as a peroxidase mimic

Yang, P., Shen, H., Tang, S., Huang, Z., Hao, Y., Luo, Z., Zhou, F., Wang, T., & Feng, W. (2018) · Microchimica Acta · doi:10.1007/s00604-018-2940-1 · Cited by 9 · see citing works

Real‐World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi‐Resistant Chronic‐Phase Chronic Myeloid Leukemia (CML‐CP) Patient Population

Breccia, M., Rossi, A. R., Giai, V., Martino, B., Fava, C., Annunziata, M., Abruzzese, E., Binotto, G., Baratè, C., Nardozza, A. P., et al. (2025) · Hematological Oncology · doi:10.1002/hon.70101 · Cited by 8 · see citing works

The importance of personalized medicine in chronic myeloid leukemia management: a narrative review

Zaker, E., Nouri, N., Sorkhizadeh, S., Ghasemirad, H., Hajijafari, A. H., & Zare, F. (2023) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-023-00411-3 · Cited by 8 · see citing works

Combination of dasatinib and okadaic acid induces apoptosis and cell cycle arrest by targeting protein phosphatase PP2A in chronic myeloid leukemia cells

Özel, B., Kıpçak, S., Avcı, Ç. B., Gündüz, C., Saydam, G., Aktan, Ç., & Günel, N. S. (2022) · Medical Oncology · doi:10.1007/s12032-021-01643-2 · Cited by 8 · see citing works

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells

Yang, Y., Liu, X., Xiao, F., Xue, S., Xu, Q., Yin, Y., Sun, H., Xu, J., Wang, H., Zhang, Q., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117573 · Cited by 7 · see citing works

The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program

Sacha, T., Szczepanek, E., Dumnicka, P., Góra‐Tybor, J., Niesiobędzka‐Krężel, J., Prejzner, W., Wasilewska, E. M., Kloczko, J. S., Ciepłuch, H., Makowska, W., et al. (2021) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2021.11.012 · Cited by 7 · see citing works

The regulation of bcr-abl in hypoxia is through the mTOR pathway

Clapper, E., Trapani, G. D., & Tonissen, K. F. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1849679 · Cited by 7 · see citing works

Systematic optimization of reverse phase ultra‐high‐performance liquid chromatography method for quantification of nilotinib and its related substances in bulk drug and pharmaceutical formulation using quality by design approach

Prasad, S. K., & Divekar, K. (2024) · Separation Science Plus · doi:10.1002/sscp.202300185 · Cited by 6 · see citing works

High-throughput formulation of reproducible 3D cancer microenvironments for drug testing in myeloid leukemia

Rudzińska, M., Turos-Korgul, L., Mukherjee, D., Podszywalow‐Bartnicka, P., Piwocka, K., & Guzowski, J. (2024) · Biofabrication · doi:10.1088/1758-5090/ad998d · Cited by 6 · see citing works

Use patterns of first-line inhibitors of tyrosine kinase and time to change to second-line therapy in chronic myeloid leukemia

Machado‐Alba, J. E., & Machado‐Duque, M. E. (2017) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-017-0484-9 · Cited by 6 · see citing works

Therapeutic Responses of Imatinib and Nilotinib among CML Patients in Hasan Sadikin Hospital Bandung

Sumantri, A. F., Oehadian, A., Wijaya, I., Vidyaniati, P., & Rahmaniati, R. (2019) · Indonesian Journal of Cancer · doi:10.33371/ijoc.v12i3.615 · Cited by 6 · see citing works

Rational Approach to New Chemical Entities with Antiproliferative Activity on Ab1 Tyrosine Kinase Encoded by the BCR-ABL Gene: An Hierarchical Biochemoinformatics Analysis

Sanches, V. H. S., Lobato, C. C., Silva, L. B., dos Santos, I. V. F., Barros, E. D. S., Maciel, A. D. A., Ferreira, E. F. B., da Costa, K. S., Espejo-Román, J. M., Rosa, J. M. C., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17111491 · Cited by 5 · see citing works

Differential prognostic impact of stratified additional chromosome abnormalities on disease progression among Malaysian chronic myeloid leukemia patients undergoing treatment with imatinib mesylate

Mariam, I. S., Norhidayah, R., Zulaikha, A. B., Yunus, N. M., Hassan, R., Ghazali, A. K., Sarina, S., Azlan, H., & Ankathil, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.720845 · Cited by 5 · see citing works

Anticancer Activity and Molecular Mechanism of Momordica cochinchinensis Seed Extract in Chronic Myeloid Leukemia Cells

Ai, Z., Ma, C., Wan, R., Yin, J., Li, G., Li, Y., & Chen, L. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.2014904 · Cited by 5 · see citing works

Quantitative Analysis of Mutant Subclones in Chronic Myeloid Leukemia: Comparison of Different Methodological Approaches

Preuner, S., Barna, A., Frommlet, F., Czurda, S., Byrgazov, K., Alikian, M., Poláková, K. M., Sacha, T., Richter, J., Lion, T., et al. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050642 · Cited by 5 · see citing works

The Role of Cytokines in Activation of Tumour-promoting Pathways and Emergence of Cancer Drug Resistance

Shirbhate, E., Singh, V. P., Kore, R., Vishwakarma, S., Veerasamy, R., Tiwari, A. K., & Rajak, H. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266284527240118041129 · Cited by 4 · see citing works

Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review

Zhang, Y. L., Chen, W., Pathak, A., Yang, Y., Yang, D., & Zhai, Y. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2022-0032 · Cited by 4 · see citing works

Agent-Based Models Help Interpret Patterns of Clinical Drug Resistance by Contextualizing Competition Between Distinct Drug Failure Modes

Leighow, S. M., Landry, B. D., Lee, M. J., Peyton, S. R., & Pritchard, J. R. (2022) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-022-00748-6 · Cited by 4 · see citing works

p38 MAPK-mediated suppression of Nrf2-MPC2 axis drives metabolic reprogramming which confers imatinib resistance in blast crisis phase of chronic myeloid leukemia

Bhat, M., Narasimhan, M., Shelar, A., Patwardhan, R., Sandur, S. K., & Govekar, R. (2025) · Experimental Cell Research · doi:10.1016/j.yexcr.2025.114870 · Cited by 3 · see citing works

Differential expression ofSHP-1in chronic myeloid leukemia

Kaeda, J., Neuman, D., Bonecker, S. T., Mills, K., Oberender, C., Amini, L., Ringel, F., Serra, A., Schwarz, M., Dörken, B., et al. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.969258 · Cited by 3 · see citing works

Electronic and Structural Insights of BCR-ABL Inhibitors Under LMC Treatment Perspective

Nascimento, É. C. M., Nascimento, L. D. A., Benicio, L. F. M. A., Alcântara, J. L. L., Pereira, W. A., & Martins, J. B. L. (2022) · Engineering materials · doi:10.1007/978-3-031-07622-0_15 · Cited by 3 · see citing works

Evaluation of Molecular Response to Imatinib Mesylate Treatment in Iranian Patients With Chronic Myeloid Leukemia

Nekoohesh, L., Rostami, S., Nikbakht, M., Mohammadi, S., Babakhani, D., Alimoghaddam, K., Ghahremani, M. H., & Chahardouli, B. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.605 · Cited by 3 · see citing works

Ultrasound arterial anomalies in patients exposed to nilotinib therapy for chronic myeloid leukemia

Sarlon-Bartoli, G., Michel, Q., Sarlon, E., Carcopino-Tusoli, M., Suchon, P., Soler, R. J., Bartoli, M. A., Brunet, D., Morange, P., & Charbonnier, A. (2021) · JMV-Journal de Médecine Vasculaire · doi:10.1016/j.jdmv.2021.02.002 · Cited by 3 · see citing works

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients – worldwide battlefield

Dvořák, P., Lysák, D., & Vokurka, S. (2015) · Neoplasma · doi:10.4149/neo_2015_021 · Cited by 2 · see citing works

Precision Deuteration in Search of Anticancer Agents: Approaches to Cancer Drug Discovery

Mourya, A., & Prajapati, N. K. (2023) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2023.0031 · Cited by 2 · see citing works

Updated review of nilotinib as frontline treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia

Breccia, M., Molica, M., & Alimena, G. (2015) · Clinical Investigation · doi:10.4155/cli.14.129 · Cited by 2 · see citing works

Is measuring plasma imatinib trough levels still an appropriate way for predicting responses in patients with chronic myeloid leukemia?

Eşkazan, A. E. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1571202 · Cited by 2 · see citing works

Mechanisms of Resistance to Tyrosine Kinase Inhibitors in Myeloid Leukemias

Alekrish, Y., Alotaibi, S., Iqbal, Z., & Aleem, A. (2025) · Cureus · doi:10.7759/cureus.86322 · Cited by 1 · see citing works

Targeting Musashi-2 to counteract senescence and resistance in chronic myeloid leukemia: enhancing the efficacy of imatinib therapy

Arif, K., Yousaf, M., & Khan, D. (2025) · BMC Cancer · doi:10.1186/s12885-025-15214-5 · Cited by 1 · see citing works

[Imatinib mesylate for chronic myeloid leukemia: in patients with initial treatment versus those with Recombinant Human IFN-α2b treatment failure].

Jiang, J., Xu, W., & Qian, W. (2015) · PubMed Central · doi:10.3785/j.issn.1008-9292.2015.03.010 · Cited by 1 · see citing works

Głęboka odpowiedź molekularna po podaniu dazatynibu w 3. linii terapii u chorego na przewlekłą białaczkę szpikową w fazie przewlekłej

Lewandowska, M., Gniot, M., Ratajczak, B., Jarmuż‐Szymczak, M., & Lewandowski, K. (2015) · Hematologia · doi:10.5603/hem.2015.0031 · Cited by 1 · see citing works

Skuteczne leczenie ratunkowe inhibitorami kinaz tyrozynowych chorego na B-komórkową ostrą białaczkę limfoblastyczną Filadelfia-dodatnią

Seferyńska, I., Ejduk, A., Solarska, I., & Warzocha, K. (2018) · Hematologia · doi:10.5603/hem.2018.0005 · Cited by 1 · see citing works

PROGNOSTIC VALUE OF CYP3A5 AND hOCT1 POLYMORPHIC GENE VARIANTS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN THE REPUBLIC OF BASHKORTOSTAN

Сафуанова, Г. Ш., Рябчикова, Н. Р., Хуснутдинова, Э. К., Karimov, D. O., & Minniakhmetov, I. R. (2019) · Гематология и трансфузиология · doi:10.35754/0234-5730-2019-64-2-165-174 · Cited by 1 · see citing works

A Single Center Study of Prescribing and Treatment Outcomes of Patients with Chronic Myeloid Leukemia

Nekoohesh, L., Ghahremani, M. H., Rostami, S., Nikbakht, M., Nekoohesh, L., Naemi, R., Mohammadi, S., Nejad, L. G., Mousavi, S. A., Vaezi, M., et al. (2020) · International Journal of Hematology-Oncology and Stem Cell Research · doi:10.18502/ijhoscr.v14i1.2324 · Cited by 1 · see citing works

Protein Flexibility and Dissociation Pathway Differentiation Can Explain Onset of Resistance Mutations in Kinases**

Shekhar, M., Smith, Z., Seeliger, M. A., & Tiwary, P. (2022) · Angewandte Chemie · doi:10.1002/ange.202200983 · Cited by 1 · see citing works

Evaluation of 389nm UV-LED to Induce Apoptosis in Leukemia Cells for Develop Implant Photonics-Device

Inada, S. A. (2019) · Biomedical Journal of Scientific & Technical Research · doi:10.26717/bjstr.2019.19.003379 · Cited by 1 · see citing works

GOLDEN fusion: a graph-oriented learning with domain-embedding network fusion for generating super gene sets in functional genomics

Li, Q., Nichols, C., Welner, R. S., Chen, J. Y., Ku, W.-S., & Yue, Z. (2026) · Briefings in Bioinformatics · doi:10.1093/bib/bbag244

Understanding life and death decisions in human leukaemias

MacEwan, D. J., Barrera, L. N., Keadsanti, S., Rushworth, S. A., Shah, N., Yuan, T., & Zaitseva, L. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140127

Additional chromosomal abnormalities at diagnosis or during tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia

Eşkazan, A. E. (2017) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2017.1295145

Association of T315I mutation with resistance to tyrosine kinase inhibitor therapy in patients with CML attended the Oncology-Hematology center in Al-Najaf city of Iraq

Rahem, R. M., Abuhmood, A. A., & Hussein, L. (2017) · Karbala International Journal of Modern Science · doi:10.1016/j.kijoms.2017.08.004

BCR/ABL1 KINASE DOMAIN MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH SECONDARY RESISTANCE TO THE IMATINIB THERAPY

Dmytrenko, I. V., Мінченко, Ж. М., & Dyagil, I. (2018) · Bulletin of Problems Biology and Medicine · doi:10.29254/2077-4214-2018-1-2-143-249-254

Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience

Saleem, U., Hafeez, T., Raza, S. A., Tahir, M., Khalid, F., & Islam, M. K. (2020) · Cureus · doi:10.7759/cureus.7826

Study on Mutation Resistance to Imatinib in Chronic Myeloid Leukemia Patients from West India

Darji, A., & Bharadia, P. D. (2021) · Science Journal of Analytical Chemistry · doi:10.11648/j.sjac.20210901.11

Pre-clinical evaluation of targeting autophagy for the treatment of Oral Squamous Cell Carcinoma

Magnano, S. (2021) · Arrow@dit (Dublin Institute of Technology)

The Effect of BCR-ABL Specific Tyrosine Kinase Inhibitors on the Thioredoxin System in Chronic Myeloid Leukemia

Clapper, E., Trapani, G. D., & Tonissen, K. F. (2021) · Hemato · doi:10.3390/hemato2020014

Biomarkers in Cancer Survival and Drug Resistance

Ikram, M., & Uddin, Z. (2022) · Springer eBooks · doi:10.1007/978-981-16-5759-7_7

Phenotypically plastic drug‐resistant chronic myeloid leukaemia cell line displays enhanced cellular dynamics in a zebrafish xenograft model

Baykal, S., Yüce, Z., & Özhan, G. (2024) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70105

Mechanisms of resistance to BCR–ABL kinase inhibitors

Diamond, J., & Melo, J. V. (2011) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2010.546920 · Cited by 55 · see citing works

Analysis of the Molecular Determinants of the Response of Chronic Myelogenous Leukaemia to Tyrosine Kinase Inhibitors

Labussière, H., Hayette, S., & Nicolini, F. E. (2007) · Current Pharmacogenomics · doi:10.2174/157016007781669231

Current aspects in resistance against tyrosine kinase inhibitors in chronic myelogenous leukemia

Balabanov, S., Braig, M., & Brümmendorf, T. H. (2014) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2014.03.003 · Cited by 77 · see citing works

Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia

Marfè, G., & Stefano, C. (2014) · Current Drug Discovery Technologies · doi:10.2174/1570163811666140212111508 · Cited by 4 · see citing works

Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia-from molecular mechanisms to clinical relevance

Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204 · see citing works